EMD Serono Expands Global Research & Development Hub in Massachusetts and Continues to Build Presence in US Pharmaceuticals

  EMD Serono Expands Global Research & Development Hub in Massachusetts and
  Continues to Build Presence in US Pharmaceuticals Market

  *Expansion demonstrates EMD Serono’s commitment to fostering
    state-of-the-art drug discovery research and clinical development in the
  *Pharma division anticipates 20% employee growth in the US by 2014
  *Billerica campus renamed EMD Serono Research & Development Institute

Business Wire

ROCKLAND, Mass. -- April 18, 2013

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced
today the continued expansion of the company’s presence in the United States,
resulting in an estimated 20% increase in EMD Serono’s employee base from last
July to the end of 2014.

“The US represents one of the fastest growing markets for our company,” said
Annalisa Jenkins, Head of Global Drug Development and Medical. “Strengthening
our presence in the US is central to our ability to deliver innovation and
value to our patients and customers. By expanding our footprint within the
Boston life sciences cluster of technology and talent, we significantly
enhance our competitive position in the US and globally.”

The expansion will primarily take place at the site in Billerica,
Massachusetts, which is being renamed the “EMD Serono Research & Development
Institute.” The renaming reflects the full scope of work that will take place
in Billerica, from early stage drug discovery research through to clinical
development and medical, and reinforces EMD Serono’s commitment to discover
and bring to market new treatments in key therapeutic areas.

In recent years, EMD Serono has invested more than $75 million in a new
state-of-the-art research facility in Massachusetts. The expansion of the
company’s drug development organization in the US marketplace is another
strong signal of EMD Serono’s commitment to be closer to customers and ensure
a stronger scientific and commercial profile in this critical pharmaceutical

James Hoyes, President of EMD Serono, added: “The Greater Boston area remains
one of the top locations for state-of-the-art drug development. Here we can
attract and retain best-in-class talent in the biopharma and life sciences
industry. We are confident that by increasing hiring in the US, we can
continue to foster innovation and a culture anchored in new possibilities.”

EMD Serono has further bolstered its US presence with recent strategic
appointments of leadership within global functional areas residing at either
its Rockland or Billerica sites, including the heads of three global Research
and Early Development platforms; Immuno-Oncology, Immunology and Neurology.
Additionally, the heads of global business franchises, including the head of
the business franchise NDD, and various other strategic leaders within the
global operations, global medical teams, global development and other global
group functions are now based in the US. The presence of these leadership
roles in a strategic region such as the US is one signal of the overall
commitment to growth of the EMD Serono global pharmaceutical footprint.

The company’s growth in the Boston area will support the advancement of its
pipeline and an ability to build partnerships with academia and the biotech
sector, while enhancing access to talent across the R&D continuum. The company
is ongoing in building its expertise in the area of oncology, immuno-oncology
and immunology, in addition to further strengthening its solid market position
in the therapeutic area of multiple sclerosis. Globally, the pharma division
of Merck KGaA, Darmstadt, Germany has four R&D hubs, in Boston, MA; Darmstadt,
Germany; Beijing, China; and Tokyo, Japan.

About EMD Serono, Inc.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader
in the US biopharmaceutical arena, integrating cutting-edge science with
unparalleled patient support systems to improve people's lives. The company
has strong market positions in neurodegenerative diseases, endocrinology and
in reproductive health. In addition, EMD Serono is growing its expertise and
presence in the area of oncology, with more than 15 projects currently in
development. With a clear focus on the patient and a leadership presence in
the biopharmaceutical industry, EMD Serono’s US footprint continues to grow,
with approximately 1,000 employees around the country and fully integrated
commercial, clinical and research operations in the company’s home state of
For more information, please visit www.emdserono.com

About Merck KGaA

Merck KGaA is a global pharmaceutical, chemical and life science company with
total revenues of € 11.2 billion in 2012, a history that began in 1668, and a
future shaped by approx. 39,000 employees in 66 countries. Its success is
characterized by innovations from entrepreneurial employees. Merck's operating
activities come under the umbrella of Merck KGaA, in which the Merck family
holds an approximately 70% interest and shareholders own the remaining
approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated
and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merckgroup.com


EMD Serono
Kristen LaVerghetta, 781-681-2065
Press spacebar to pause and continue. Press esc to stop.